Summary

in vitro, in vitro diagnostic, diagnostic, IVD, COVID, 19, rapid, antigen, test, lateral flow assay, LFA, animal, drug, opioid, oral, cancer, laboratory, EUA, Flu, multiplex, multi-target, multitarget, spike, protein, nucleocapsid, Fentanyl, Xylazine, harm., reduction, substance, abuse, misuse, avian influenza, AIV, bird flu, screening, surveillance, saliva, H5N1, H7N1, H7N3, Flu A, Flu B, influenza A, influenza B, influenza, women's health, sepsis, Group B Strep, Group B Streptococcus, Streptococcus

Description

BioSynchronicity Corporation is a Woman Owned Small Business (WOSB) focused on Biotechnology Research and Development, design and manufacturing of diagnostics for the medical, dental, and veterinary industries, as well as laboratory services, next generation genomic sequencing, including preventative early cancer screening, surveillance, and recurrence testing. Our flagship BioSynchronicity C-Sync™ Lateral Flow Assay technology platform was launched in 2020. Our C-Sync™ COVID 19 multi target rapid antigen test detecting both nucleocapsid and spike proteins was granted an EUA by the FDA in 2023. A new innovative multiplex combination test for COVID and Flu, as well as an assay for Avian Influenza are in development. Graphene based electrochemical biosensor assays for the early quantitative detection of infectious diseases and other biomarkers are in the pipeline.

Profile

  • Incorporated in
    Washington
  • Established since
    2020
  • Main/Branch
    Branch

Address

Contact